Start of ‘Warring States’ in hepatitis C market

The hepatitis C treatment market has met the ‘Warring States’ period.

The Ministry of Food and Drug Safety(MFDS) has approved ‘Mavyret,’ an AbbVie Korea’s hepatitis C therapy, on 12 January.

‘Mavyret’ was approved as a hepatitis C therapy type 1 to 6 from the U.S. FDA on 3 August 2017, and is available for hepatitis patients having cirrhosis symptoms with nephritis or dialysis.

The FDA has g...